TABLE 3.
Activity of protease inhibitors in HIV-2ROD and site-directed mutantsa
| Protease inhibitor | EC50 (nM) (fold change compared to HIV-2ROD)
|
|||
|---|---|---|---|---|
| HIV-2ROD | G17N | V47A | G17N/V47A | |
| ATV | 34 ± 3 | 20 ± 1 (0.6) | 5 ± 0.5 (0.1) | 3 ± 0.5 (0.1) |
| APV | 855 ± 55 | 583 ± 28 (0.7) | 630 ± 118 (0.7) | 404 ± 20 (0.5) |
| DRV | 9 ± 2 | 6 ± 0.4 (0.7) | 10 ± 1 (1.1) | 8 ± 0.3 (0.9) |
| IDV | 65 ± 5 | 52 ± 5 (0.8) | 34 ± 5 (0.5) | 24 ± 1 (0.5) |
| LPV | 35 ± 2 | 28 ± 1 (0.8) | 340 ± 15 (9.7) | 260 ± 25 (7.4) |
| NFV | 281 ± 32 | 199 ± 9 (0.7) | 177 ± 17 (0.6) | 100 ± 34 (0.4) |
| RTV | 421 ± 10 | 310 ± 23 (0.7) | 115 ± 6 (0.3) | 84 ± 5 (0.2) |
| SQV | 3.6 ± 0.6 | 2.2 ± 0.1 (0.6) | 0.2 ± 0.2 (0.1) | 0.2 ± .07 (0.1) |
a
Each EC50 value represents the mean of three determinations.